Ms. Nadia  Dac

Vice President & Chief Commercial Officer

Ms. Debra K. Bowes M.T

Chief Bus. Devel. Officer

Dr. Catherine A. Melfi Ph.D.

Chief Regulatory Officer & Vice President of Regulatory Affairs and Quality Systems

Dr. J. Steven Whitaker J.D., M.D.

Vice President of Clinical Devel. & Chief Medical Officer

Mr. Michael A. Jacobsen

Chief Accounting Officer, Vice President of Fin. & Treasurer

Mr. Peter B. Cancelmo J.D.

Vice President, Gen. Counsel & Corporation Sec.

Mr. Peter W. Williams

Vice President of HR

Dr. Pamela Pierce Palmer M.D., Ph.D.

Co-Founder

Dr. Gregory A. Demopulos M.D.

Co-Founder, Chairman, Chief Executive Officer & Pres

Dr. George A. Gaitanaris M.D., Ph.D.

Chief Scientific Officer & Vice President of Science

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Omeros Corporation (NASDAQ:OMER ) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET Company Participants Jennifer Williams - Investor Relations Dr. Greg Demopulos - Chairman and CEO Mike Jacobsen - Chief Accounting Officer Cathy Melfi - Chief Regulatory Officer Steve Whitaker - Chief Clinical Officer Nadia Dac - Vice President and CCO Conference Call Participants Colin Bristow - UBS Steve Brozak - WBB Securities Mary Kate - Bank of America Brandon Folkes - Cantor Serge Belanger - Needham & Company Operator Good afternoon. And welcome to today's earnings call from Omeros Corporation.

Omeros Corporation (OMER) Q4 2022 Earnings Call Transcript

A $200 million milestone payment sparked a rally in the biopharma's shares this week.

Why Omeros Stock Bolted Higher This Week

Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang some investors were worried about. With the additional $200M cash, now the enterprise value of the company is around $115M, which we believe is still very cheap for the company's compelling MASP-2 platform.

Omeros: $200M Added To The Company's Balance Sheet, Upgrading To Strong Buy

The stock price of Omeros Corporation (NASDAQ: OMER) surged by over 50% intraday today. This is why.

OMER Stock: Over 50% Surge Explained

The Omeros will now be able to fund operations at least through 2025.

Why Omeros Corporation Stock Is Skyrocketing Today

Powered by AI

Omeros Corporation

3.86